<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19930566</article-id><article-id pub-id-type="pmc">2788534</article-id><article-id pub-id-type="publisher-id">1745-6215-10-105</article-id><article-id pub-id-type="doi">10.1186/1745-6215-10-105</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study protocol</subject></subj-group></article-categories><title-group><article-title>The Toronto prehospital hypertonic resuscitation-head injury and multi organ dysfunction trial (TOPHR HIT) - Methods and data collection tools</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Morrison</surname><given-names>Laurie J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>morrisonl@smh.toronto.on.ca</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Rizoli</surname><given-names>Sandro B</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I4">4</xref><email>sandro.rizoli@sunnybrook.ca</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Schwartz</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I5">5</xref><xref ref-type="aff" rid="I6">6</xref><email>bschwartz@socpc.ca</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Rhind</surname><given-names>Shawn G</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>shawn.rhind@drdc-rddc.goc.ca</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Simitciu</surname><given-names>Merita</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>singhs@smh.toronto.on.ca</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Perreira</surname><given-names>Tyrone</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>perreirat@smh.toronto.on.ca</email></contrib><contrib contrib-type="author" id="A7"><name><surname>MacDonald</surname><given-names>Russell</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I9">9</xref><email>rmacdonald@ornge.ca</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Trompeo</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>singhs@smh.toronto.on.ca</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Stuss</surname><given-names>Donald T</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>dstuss@rotman-baycrest.on.ca</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Black</surname><given-names>Sandra E</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>sandra.black@sw.ca</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Kiss</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I12">12</xref><email>alex.kiss@ices.on.ca</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Baker</surname><given-names>Andrew J</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I8">8</xref><email>bakera@smh.toronto.on.ca</email></contrib></contrib-group><aff id="I1"><label>1</label>Rescu, Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael's Hospital, 30 Bond St, Toronto Ontario, M5B 1W8, Canada</aff><aff id="I2"><label>2</label>Department of Medicine, University of Toronto, 1 Kings College Circle, Toronto, Ontario, M5S 1A1, Canada</aff><aff id="I3"><label>3</label>Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada</aff><aff id="I4"><label>4</label>Department of Surgery, University of Toronto, 1 Kings College Circle, Toronto Ontario, M5S 1A1, Canada</aff><aff id="I5"><label>5</label>Sunnybrook Osler Centre for Prehospital Care, 10 Carlson Court, Suite 640, Etobicoke, Ontario, M9W 7K6, Canada</aff><aff id="I6"><label>6</label>Department of Family and Community Medicine, University of Toronto, 1 Kings College Circle, Toronto Ontario, M5S 1A1, Canada</aff><aff id="I7"><label>7</label>Defense Research and Development Canada, 1133 Sheppard Avenue West, Toronto Ontario, M3M 3B9, Canada</aff><aff id="I8"><label>8</label>Department of Anaesthesia, University of Toronto, 1 Kings College Circle, Toronto Ontario, M5S 1A1, Canada</aff><aff id="I9"><label>9</label>Ornge Transport Medicine, 20 Carlson Court, Suite 400, Toronto Ontario, Canada</aff><aff id="I10"><label>10</label>University of Turin, Via Po, 53-I-10124 Torino, Italy</aff><aff id="I11"><label>11</label>Rotman Research Institute, Baycrest, 3560 Bathurst Street, Toronto Ontario, M6A 2E1, Canada</aff><aff id="I12"><label>12</label>Institute of Clinical and Evaluative Sciences, 2075 Bayview Avenue, Toronto Ontario, M9W 7K6, Canada</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>20</day><month>11</month><year>2009</year></pub-date><volume>10</volume><fpage>105</fpage><lpage>105</lpage><history><date date-type="received"><day>20</day><month>10</month><year>2009</year></date><date date-type="accepted"><day>20</day><month>11</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9;2009 Morrison et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Morrison et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.trialsjournal.com/content/10/1/105"/><abstract><sec><title>Background</title><p>Clinical trials evaluating the use of hypertonic saline in the treatment of hypovolemia and head trauma suggest no survival superiority over normal saline; however subgroup analyses suggest there may be a reduction in the inflammatory response and multiorgan failure which may lead to better survival and enhanced neurocognitive function. We describe a feasibility study of randomizing head injured patients to hypertonic saline and dextran vs. normal saline administration in the out of hospital setting.</p></sec><sec><title>Methods/Design</title><p>This feasibility study employs a randomized, placebo-controlled design evaluating normal saline compared with a single dose of 250 ml of 7.5% hypertonic saline in 6% dextran 70 in the management of traumatic brain injuries. The primary feasibility endpoints of the trial were: 1) baseline survival rates for the treatment and control group to aid in the design of a definitive multicentre trial, 2) randomization compliance rate, 3) ease of protocol implementation in the out-of-hospital setting, and 4) adverse event rate of HSD infusion.</p><p>The secondary objectives include measuring the effect of HSD in modulating the immuno-inflammatory response to severe head injury and its effect on modulating the release of neuro-biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting patient outcome and clinical response to HSD intervention; evaluating effects of HSD on brain atrophy post-injury and neurocognitive and neuropsychological outcomes.</p></sec><sec><title>Discussion</title><p>We anticipate three aspects of the trial will present challenges to trial success; ethical demands associated with a waiver of consent trial, challenging follow up and comprehensive accurate timely data collection of patient identifiers and clinical or laboratory values. In addition all the data collection tools had to be derived de novo as none existed in the literature.</p></sec><sec><title>Trial registration number</title><p>NCT00878631</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Hypertonic Saline provides an alternative to large volume time limited resuscitation to restore hemodynamic stability and minimize the posttraumatic organ dysfunction. There is however, no clear clinical evidence supporting the hypothesis that hypertonic saline is the optimal choice for prehospital trauma resuscitation, specifically with respect to brain injury. Most of the current evidence demonstrating anti-inflammatory and immunological properties of hypertonic saline comes from experimental models (animal and isolated cell preparations) and remains untested in humans. A recent meta-analysis demonstrated that hypotensive patients with severe head injury are twice as likely to survive if resuscitated with hypertonic saline in dextran (HSD) compared with isotonic crystalloids [<xref ref-type="bibr" rid="B1">1</xref>] In separate clinical trials, HSD resuscitation was associated with a reduced incidence of acute respiratory distress syndrome (ARDS), renal failure and infectious complications [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B4">4</xref>]. Because of the compelling current evidence suggesting the effectiveness of HSD and the known burden of traumatic brain injury (TBI) and multiorgan dysfunction, this question requires direct evaluation.</p><p>The application of rigorous clinical trial methodology in the prehospital setting requires overcoming a number of challenges unique to the setting. We conducted a feasibility study prior to implementing a larger randomized clinical efficacy trial. This feasibility study is significantly different from other prehospital trauma trials because it is designed by investigators from multiple disciplines including immunology, neurology, surgery, anaesthesia, neuropsychology and neuroimaging to address aspects of TBI not evaluated previously and employs a randomized clinical trial design and waiver of consent. In addition to the primary study objective of survival at 30 days we plan to evaluate circulating and cellular immunomodulation within the first 24 hours, neurocognitive and neuropsychological testing at 4 and 12 months, and structural damage through MRI scanning up to 4 months post trauma.</p><p>We report the methods in detail and have appended the data collection tools and case report forms for this feasibility study. All case report forms and data collection forms were created by the investigators as prior forms did not exist previously in the literature.</p></sec><sec><title>Methods/Design</title><sec><title>Study design</title><p>The Toronto Prehospital Hypertonic Resuscitation-Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT) is a randomized, placebo-controlled trial of blunt trauma patients with head injuries. The study compares a group receiving normal saline according to a paramedic's protocol, with a treatment group receiving a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 (RescueFlow<sup>&#x000ae; </sup>BioPhausia AB, Stockholm Sweden). The study was approved by the Canadian Therapeutic Products Directorate Control Number 092523 and registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinical.trials.gov">http://www.clinical.trials.gov</ext-link>. Inclusion and exclusion criteria are summarized in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>.</p></sec><sec><title>Study Objective</title><p>The primary objective of this study is to report feasibility in accordance with the methodology described by Lancaster and Dodds [<xref ref-type="bibr" rid="B5">5</xref>], specifically addressing:</p><p>1) baseline survival rates for the treatment and control group to aid in the design of a definitive multicentre trial;</p><p>2) randomization compliance rate;</p><p>3) ease of protocol implementation in the out-of-hospital setting;</p><p>4) adverse event rate of HSD infusion.</p><p>The secondary objectives include measuring the effect of HSD in modulating the immuno-inflammatory response to severe head injury and its effect on modulating the release of neuro-biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting patient outcome and clinical response to HSD intervention; and evaluating effects of HSD on brain atrophy post-injury and neurocognitive and neuropsychological outcomes.</p></sec><sec><title>Randomization</title><p>The study employs a block randomization by station derived from a computer-generated random number table. Blocks of two study packages are assigned to each ambulance vehicle/aircraft. Paramedics are blinded to the treatment assigned until package opening. A field logistics research coordinator is responsible for randomization compliance at the vehicle level through daily checks. Compliance at the patient will be verified through the randomization number of the product label and recorded on the data checklist.</p></sec><sec><title>Setting</title><p>The trial setting is the city of Toronto with a population of at 2.5 million served by an emergency medical services system employing approximately 430 Advanced Life Support Paramedics, 570 Basic Life Support Paramedics and 3,000 Firefighter first responders under the same medical direction. In addition, the trial includes one Ornge Transport Medicine rotor wing base with two helicopters and 32 critical care flight paramedics providing responses from accident scenes outside the city of Toronto within south central Ontario. Enrolled patients will be directly admitted to two adult designated regional Trauma Centers.</p></sec><sec><title>Intervention Protocol</title><p>All patients will be treated according to research medical directives (Additional File <xref ref-type="supplementary-material" rid="S2">2</xref>) based on a standardized provincial out of hospital trauma treatment protocol [<xref ref-type="bibr" rid="B6">6</xref>]. The study solution is started within 4 hours of the time the emergency call was received at ambulance dispatch. Samples of peripheral blood will be collected upon emergency department (ED) arrival, 12, 24 and 48 hours after ED arrival from a vein remote from the venous access site for the study infusion. Blood samples will be collected in heparinized and non-additive vacutainers by a single trained lab technician and immediately (within 1-h) shipped to a single designated laboratory for whole blood flow cytometric cellular analyses and measurement of circulating molecular immuno-inflammatory markers. Serum will be frozen for subsequent analyses. Whole blood will be incubated with saturating concentrations of the adhesion (CD62L-FITC, CD11b-PE), degranulation (CD66b-FITC, CD63-PE), apoptotic/necrotic (Annexin V-PE, 7-AAD, Active Caspase-3, CD95-Fas, CD178-FasL) markers, in conjunction with CD14-APC surface staining (to differentiate leukocyte subsets). Results will be acquired on a Becton Dickinson dual-laser (488 nm and 635 nm) BD FACSCalibur flow cytometer using CellQuest software. Serum samples will be analyzed for pro-/anti-inflammatory cytokines (TNF-&#x003b1;, IL-10), soluble leukocyte and endothelial-derived adhesion molecules (sICAM-1, sVCAM-1, sE-selectin, sL-selectin), pro-/anti-apoptotic molecules (sCD95, sCD95L, TNF-RI, sFas/FasL) and neuro-biomarkers of brain injury (S100B, NSE, MBP) (Additional File <xref ref-type="supplementary-material" rid="S3">3</xref>).</p><p>Magnetic Resonance Imaging on a 1.5 Tesla General Electric Signa Magnet is planned for completion at 4 months for consenting patients using a standardized protocol (Additional File <xref ref-type="supplementary-material" rid="S4">4</xref>, <xref ref-type="supplementary-material" rid="S5">5</xref>, <xref ref-type="supplementary-material" rid="S6">6</xref>, <xref ref-type="supplementary-material" rid="S7">7</xref>); a 3D 1.3 mm thick, T1-weighted, series (TE 4-2, TR 35, flip angle 35), an interleaved 3 mm thick PD and T2-weighted spin echo sequence (TE 39/80, TR 3000, flip angle 90) (Additional File <xref ref-type="supplementary-material" rid="S6">6</xref>), a gradient echo sequence and Diffusion Tensor Imaging (11 directions) (Additional File <xref ref-type="supplementary-material" rid="S7">7</xref>); tissue segmentation and parcellation including lesion quantification [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B12">12</xref>] using previously published in-house software as well as ANALYZE software [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B13">13</xref>].</p></sec><sec><title>Study outcomes</title><sec><title>Survival</title><p>The primary clinical outcome is survival at 30 days.</p><p>Secondary clinical outcomes are survival at 48 hours and to hospital discharge.</p></sec><sec><title>Neurocognitive Outcomes</title><p>At discharge:</p><p>&#x02022; Cerebral Performance Category [<xref ref-type="bibr" rid="B14">14</xref>]</p><p>At 4 months:</p><p>&#x02022; Functional Independence Measure (FIM)[<xref ref-type="bibr" rid="B15">15</xref>]</p><p>&#x02022; Disability Rating Scale (DRS) [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B19">19</xref>]</p><p>&#x02022; Glasgow Outcome Scale (GOS)[<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]</p><p>&#x02022; Glasgow Outcome Scale Extended (GOS Extended)[<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B20">20</xref>]</p></sec><sec><title>Neuropsychological Outcomes</title><p>At 4 months:</p><p>&#x02022; Learning and Memory</p><p>&#x025cb;California Verbal Learning Test[<xref ref-type="bibr" rid="B22">22</xref>]</p><p>&#x025cb;Wechsler Memory Scale-Revised Immediate and Delayed Visual Reproduction[<xref ref-type="bibr" rid="B23">23</xref>]</p><p>&#x025cb;Rey-Osterreith Immediate and Delayed Memory[<xref ref-type="bibr" rid="B24">24</xref>]</p><p>&#x02022; Working Memory</p><p>&#x025cb;WMS-R Backward Digit Span[<xref ref-type="bibr" rid="B23">23</xref>]</p><p>&#x02022; Executive Function</p><p>&#x025cb;FAS Verbal Fluency[<xref ref-type="bibr" rid="B25">25</xref>]</p><p>&#x025cb;Wisconsin Card Sorting Test[<xref ref-type="bibr" rid="B26">26</xref>]</p><p>&#x025cb;Trail Making Test Parts A &#x00026; B[<xref ref-type="bibr" rid="B27">27</xref>]]</p><p>&#x025cb;Stroop Test[<xref ref-type="bibr" rid="B28">28</xref>]</p><p>&#x025cb;Object Alternation[<xref ref-type="bibr" rid="B29">29</xref>]</p><p>&#x025cb;WMS-R Forward Digit Span[<xref ref-type="bibr" rid="B23">23</xref>]</p><p>&#x02022; Language Function</p><p>&#x025cb;Boston Naming Test[<xref ref-type="bibr" rid="B27">27</xref>]</p><p>&#x025cb;Semantic Fluency[<xref ref-type="bibr" rid="B25">25</xref>]</p><p>&#x02022; Visuospatial Function</p><p>&#x025cb;Judgment of Line Orientation[<xref ref-type="bibr" rid="B30">30</xref>]</p><p>&#x025cb;Facial Recognition[<xref ref-type="bibr" rid="B30">30</xref>]</p><p>&#x02022; Speed of Processing</p><p>&#x025cb;WAIS-R Digit Symbol[<xref ref-type="bibr" rid="B31">31</xref>]</p><p>&#x025cb;Trail Making Test Part A[<xref ref-type="bibr" rid="B27">27</xref>]</p><p>&#x02022; Beck Depression Scale[<xref ref-type="bibr" rid="B32">32</xref>].</p><p>A focused attention reaction time test[<xref ref-type="bibr" rid="B33">33</xref>,<xref ref-type="bibr" rid="B34">34</xref>] with varying levels of complexity will be administered at 12 months.</p></sec></sec><sec><title>Structural Outcomes</title><p>The structural brain parameters will be evaluated by MRI as described above [<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B10">10</xref>] (Additional File <xref ref-type="supplementary-material" rid="S4">4</xref>, <xref ref-type="supplementary-material" rid="S5">5</xref>, <xref ref-type="supplementary-material" rid="S6">6</xref>, <xref ref-type="supplementary-material" rid="S7">7</xref>) and will be measured by a published protocol [<xref ref-type="bibr" rid="B8">8</xref>] (Additional File <xref ref-type="supplementary-material" rid="S8">8</xref>, <xref ref-type="supplementary-material" rid="S9">9</xref>). This includes evaluation of:</p><p>&#x02022; Total brain volume and regional volumes (frontal anterior and medial temporal) and medial temporal to be the width [<xref ref-type="bibr" rid="B8">8</xref>] (Proton Density T2T1-Weighted) [<xref ref-type="bibr" rid="B7">7</xref>]</p><p>&#x02022; Fractional Anistropy (Diffusion Tensor Imaging)</p><p>&#x02022; N-acetyl-aspartate/creatinine ratio (Proton magnetic resonance spectroscopy) [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]</p><p>&#x02022; Haemosiderin deposits on gradient echo MRI</p><p>&#x02022; Serum S100B astrocytosis marker of brain injury and C Reactive Protein [<xref ref-type="bibr" rid="B35">35</xref>]</p></sec><sec><title>Cellular and Molecular Biomarkers</title><p>Whole blood and circulating immuno-inflammatory markers will be measured on hospital arrival and at 12, 24 and 48 hours later</p><p>&#x02022; Total leukocyte count and differential; neutrophil and monocyte surface expression of cellular adhesion molecules and degranulation markers: L-selectin (CD62L) and &#x003b2;<sub>2</sub>-integrin (CD11b) [<xref ref-type="bibr" rid="B36">36</xref>]</p><p>&#x02022; Leukocyte apoptotic/necrotic surface and intracellular markers (Annexin V-PE, 7-AAD, Active Caspase-3, Fas (CD95), FasL (CD178) [<xref ref-type="bibr" rid="B37">37</xref>-<xref ref-type="bibr" rid="B42">42</xref>]</p><p>&#x02022; Soluble pro-/anti-apoptotic molecules (sCD95, sCD95L, TNF-RI, sFas/FasL)[<xref ref-type="bibr" rid="B43">43</xref>]</p><p>&#x02022; Leukocyte and endothelial-derived serum soluble adhesion molecule concentrations: intercellular adhesion molecule-1 (sICAM-1), vascular adhesion molecule-1 (sVCAM-1), sE-selectin, sL-selectin [<xref ref-type="bibr" rid="B44">44</xref>-<xref ref-type="bibr" rid="B46">46</xref>]</p><p>&#x02022; Pro and anti-inflammatory cytokine expression: tumour necrosis factor (TNF)-&#x003b1;, and interleukin (IL)-10 [<xref ref-type="bibr" rid="B37">37</xref>,<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>];</p><p>&#x02022; PT/PTT, tissue factor (TF), thrombomodulin (TM), fibrinogen, platelet count and Hg; Ionized calcium, and pH [<xref ref-type="bibr" rid="B49">49</xref>]</p><p>&#x02022; Serum sodium, chloride and osmolarity</p></sec><sec><title>Safety and Dependability</title><p>The Paramedic Data Checklist (Additional File <xref ref-type="supplementary-material" rid="S10">10</xref>) and both the land and air prehospital (Additional File <xref ref-type="supplementary-material" rid="S11">11</xref>&#x00026;<xref ref-type="supplementary-material" rid="S12">12</xref>) and inhospital (Additional File <xref ref-type="supplementary-material" rid="S13">13</xref>) Case Report Forms explicitly ask whether or not adverse drug reactions with a definite causal relationship to the HSD have occurred. These adverse drug reactions will be predetermined by the Steering Committee based on the literature where possible. (Table <xref ref-type="table" rid="T1">1</xref>) The Steering Committee will validate all outcomes and determined adverse events blinded to treatment assignment. This feasibility trial is approved by the Institutional Research Ethics Board.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Adverse Event Definitions</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Event</th><th align="left">Expected</th><th align="left">Unexpected</th></tr></thead><tbody><tr><td align="left"><bold>Brain Injury</bold><break/><bold>(Serious)</bold></td><td align="left"><bold>Demyelination</bold><break/>Any text reference in imaging reports to 'Central Pontine Myelinosis or Pontine Hyperintensity' in any MRI report during hospital stay</td><td align="left"><bold>Subarachnoid Hemmorhage</bold><break/>Any text reference in imaging reports of CT of MRI within 24 hours of arrival to Emergency Department to 'Subarachnoid Hemmorhage or SAH' when the first CT scan was normal</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left"><bold>Anaphylactoid Reaction</bold><break/><bold>(Serious)</bold></td><td align="left">Any text reference in physician notes within the first 24 hours of arrival to Emergency Department to 'anaphylactoid reaction'</td><td/></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left"><bold>Prolonged Partial Thromboplastin Time</bold><break/><bold>(Non serious)</bold></td><td align="center">Normal up to 40<break/>May see up to 85 with HSD</td><td align="center">&#x0003e; 100</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left"><bold>International Normalized Ratio</bold><break/><bold>(Non serious)</bold></td><td align="center">Normal up to 1.5<break/>May see up to 3.0 with HSD</td><td align="center">&#x0003e; 3.0</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left"><bold>Serum Sodium</bold><break/><bold>(Non serious)</bold></td><td align="center">Normal range 135-147<break/>May see up to 158 with HSD</td><td align="center">&#x0003e; 160</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left"><bold>Serum Osmolarity</bold><break/><bold>(Non serious)</bold></td><td align="center">Normal range 310-330<break/>May see up to 350 with HSD without alcohol</td><td align="center">&#x0003e; 350 without alcohols</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left"><bold>Serum Chloride</bold><break/><bold>(Non serious)</bold></td><td align="center">Normal range 96-108<break/>May see up to 145</td><td align="center">&#x0003e;150</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td align="left"><bold>Rouleau formation</bold><break/><bold>(Non serious)</bold></td><td align="center">May be present</td><td/></tr></tbody></table><table-wrap-foot><p>MRI Magnetic Resonance Imaging</p><p>CT Computerized Tomography Scan</p><p>SAH Subarachnoid Hemmorhage</p></table-wrap-foot></table-wrap></sec><sec><title>Data Management</title><p>Paramedics complete a data checklist (Additional File <xref ref-type="supplementary-material" rid="S10">10</xref>) and standardized provincial patient care record. A single paramedic data abstractor will abstract data from the paramedic checklist and patient care record onto a prehospital case report form (Additional File <xref ref-type="supplementary-material" rid="S11">11</xref>). Site specific inhospital research staff will abstract data from the patient's chart daily and completed an inhospital case report form (Additional File <xref ref-type="supplementary-material" rid="S13">13</xref>). In-hospital patient data includes the interpretation of head CT scans employing the Marshall Classification system [<xref ref-type="bibr" rid="B50">50</xref>] as well as the Injury Severity Score [<xref ref-type="bibr" rid="B51">51</xref>]. Measures of organ dysfunction: Acute Physiologic and Chronic Health Evaluation (APACHE II)[<xref ref-type="bibr" rid="B52">52</xref>,<xref ref-type="bibr" rid="B53">53</xref>], Sequential Organ Failure Assessment (SOFA) [<xref ref-type="bibr" rid="B54">54</xref>] and Multiple Organ Dysfunction Score (MODS)[<xref ref-type="bibr" rid="B55">55</xref>] will be evaluated at ICU admission. In addition, SOFA and MODS will be recorded every other day until ICU discharge. Data entry onto a web based (prehospital data) or SAS version 8.0 interface (inhospital and follow up data) will be performed by a single trained data entry specialist.</p></sec><sec><title>Analysis Plan</title><p>This is a feasibility study of two year's duration with a projected screening of 130 patients and recruitment of 100. The primary outcome measure, change in the proportion surviving 30 days post trauma between the treatment and control groups, will be analyzed by means of a generalized linear mixed model which included covariates of interest. The two groups are not expected to be different at baseline, and it is hypothesized that the treatment group would show a 20% decrease in mortality at 30 days post trauma whereas the control group would remain unchanged. To derive a reduced subset of risk factors for the predictor models, acceptable model building strategies are planned (i.e. dropping variables showing extremely small variability and those found to be highly correlated (i.e. correlation coefficient &#x02265;0.8)). Treatment and time factors will be analyzed using a generalized linear mixed models of the secondary outcome repeated measures: the change in mortality after discharge over time as well as the neurocognitive and neuropsychological outcome summary scores. For secondary outcome analyses, the alpha will be adjusted to account for multiple comparisons. Where there is more than one measure for a neuropsychological test (e.g., processing speed, working memory, visuospatial, language, verbal memory, non-verbal memory - with the exception of executive processes, since different measures relate to different brain regions), a composite or prototypical measure will be derived from group comparison. Serial changes in all secondary immune modulation measures, neuro-biomarkers, neurocognitive and neuropsychological outcomes, and structural imaging measures will be evaluated by two-way ANOVA for repeated measures. All analysis will be conducted blinded to treatment assignment.</p></sec><sec><title>Ethical Considerations</title><p>We received waiver of consent approval in accordance with the Tri-Council Policy Agreement <ext-link ext-link-type="uri" xlink:href="http://www.pre.ethics.gc.ca/english/policystatement/policystatement.cfm">http://www.pre.ethics.gc.ca/english/policystatement/policystatement.cfm</ext-link>. We will seek consent from the surviving patients or the families of non survivors to analyze the blood results of all randomized patients. An itemized consent will be used where appropriate to record simultaneously consent for all follow up tests and evaluation of surviving patients.</p></sec></sec><sec><title>Discussion</title><p>The metaanalysis by Wade et al[<xref ref-type="bibr" rid="B1">1</xref>] suggested TBI was the cohort of patients most likely to demonstrate significant changes with HSD resuscitation. This study is designed to test the feasibility of randomizing patient in the prehospital setting to this cohort of patients and explore through additional tests, the important immunological, serum markers, structural changes and neuropsychological and neurocognitive outcomes in addition to the traditional survival outcomes.</p><p>We anticipate three aspects of the trial will present challenges to trial success; ethical demands, challenging follow up and comprehensive accurate timely data collection of patient identifiers and clinical or laboratory values. The ethical considerations are probably the most challenging as we will have to secure consent to analyze the blood of non survivors from families who have suffered an unexpected and devastating loss through trauma.</p><p>Additionally, we are concerned that many patients will be lost to follow up as individuals who survive TBI may be unable to return to their previous address or place of occupation and are very dependent on family. If important links to the family are not established during the first hospitalization and maintained post discharge we may be unable to find all the patients. In addition, the structural and neurocognitive and neuro psychological tests require a return visit to hospital. This may place additional demands on the family and care giver who may be overwhelmed given the functionality of some traumatic brain patients.</p><p>Finally, we anticipate two types of patients will provide unique challenges to data collection: those who die in the Emergency Department and those who met the Glasgow Coma Scale criteria for enrolment however this finding was attributed to drugs or alcohol rather than brain injury and they were discharged from the Emergency Department within hours of the accident. Strategies are in place to address these issues a priori in advance of the trial. Those who die soon after arrival in the Emergency Department often require the coroner's intervention and traditionally the charts are instantly sequestered by the coroner's staff. They commonly are unidentified and therefore it will be hard to find their health care advocate who can consent to using their blood and outcome data up until their death. We hope to overcome this with an agreement in principle with the provincial coroner to allow access to the chart at the coroner's office. We have developed a working practice with the coroner's office to confirm identification and next of kin data at the time of body retrieval</p><p>We anticipate the patients who met the GCS eligibility criteria based on alcohol consumption and are discharged relatively quickly from the Emergency Department will be hard to track down. There will be insufficient time to identify them correctly or confirm their demographic information and next of kin prior to discharge and follow up of the non brain injured group will be challenging. We will use a hierarchical approach to find these patients including government health care billing number, police report, Emergency Department report, Ambulance call report, web based telephone listings, newspapers which identify the individual based on the notoriety of the event. In addition, each receiving hospital had an active trauma registry which tracked the patients to conduct a functional evaluation at 30 days post-discharge. The surgical investigators have offered to confirm identification and obtain consent in their outpatient clinics if the patients return for follow up. This may prove to be helpful as many of these patients require forms completed by the physician for return to work, disability, insurance etc.</p><p>This study incorporates several unique features which may be helpful to subsequent trials. It is a feasibility design that follows a rigorous published methodology. It evaluates the feasibility of the out of hospital randomization as well as the inhospital data capture and analysis of complicated critical care variables, immunological markers, CT and MRI studies, and neurocognitive evaluation. The data capture forms appended to this document had to be created by the investigators as none could be found in the literature despite numerous studies in a similar cohort of patients. This should save others time and permit a more standardized data capture for future trials should they prove useful when reviewed by our peers. We hope providing the methodology will encourage others to test the feasibility of a randomized controlled trial before implementation in the complicated and costly out of hospital arena.</p></sec><sec><title>Abbreviations</title><p>ICU: Intensive Care Unit; CT: Computerized Tomography; MRI: Magnetic Resonance Imaging; All other short forms are written in full with first use.</p></sec><sec><title>Competing interests</title><p>All committee members were free of conflict of interest with respect to the study fluid manufacturer, study results and the funding source Defense Research and Development Canada (DRDC). Sandro B. Rizoli was a DRDC grant recipient and Shawn G. Rhind was a DRDC employee. Biophausia Sweden provided the study fluid (RescueFlow) free of charge without obligation to the investigators for the duration of the trial.</p></sec><sec><title>Authors' contributions</title><p>LJMchaired the steering committee, designed the study, wrote the protocol drafts, drafted the manuscript, implemented the study. SRconceived the study, participated on the steering committee, helped to design the study, contributed to protocol and manuscript drafts and helped to implement the study, received peer review funding for the project, and participated in the planning of the immuno-inflammatory and serum neuro-biomarkers substudies. BSparticipated on the steering committee, helped to design the study, contributed to protocol and manuscript drafts and helped to implement the study in the land EMS system. SRparticipated on the steering committee, helped to design the study, contributed to protocol and manuscript drafts, directed the immuno-inflammatory and serum neuro-biomarkers substudies. MSparticipated on the steering committee, contributed to protocol and manuscript drafts, coordinated the trial with a focus on long term follow up and consent. TPparticipated on the steering committee, contributed to protocol and manuscript drafts, provided the oversight on trial coordination and implementation. RMparticipated on the steering committee, contributed to protocol and manuscript drafts, and helped to implement the study in the air EMS system.</p><p>ATcontributed to manuscript drafts, planned the analysis, set up the data management system under the direction of Alex Kiss. DTSparticipated on the steering committee, helped to design the study, contributed to protocol and manuscript drafts, directed the neurocognitive and neuropsychological outcomes substudy. SBparticipated on the steering committee, helped to design the study, contributed to protocol and manuscript drafts, directed the evaluation of brain atrophy post-injury substudy. AKcontributed to protocol and manuscript drafts planned the analysis, set up the data management system.</p><p>ABparticipated on the steering committee, helped to design the study, contributed to protocol and manuscript drafts and helped to implement the study and participated in the planning of the immuno-inflammatory and serum neuro-biomarkers substudies.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Inclusion and exclusion criteria.</p></caption><media xlink:href="1745-6215-10-105-S1.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p>Medical Directives.</p></caption><media xlink:href="1745-6215-10-105-S2.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p>Blood laboratory Method.</p></caption><media xlink:href="1745-6215-10-105-S3.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p>MRI acquisition parameters.</p></caption><media xlink:href="1745-6215-10-105-S4.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S5"><caption><title>Additional file 5</title><p>MRI Scan Parameters.</p></caption><media xlink:href="1745-6215-10-105-S5.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S6"><caption><title>Additional file 6</title><p>MRI brain atrophy.</p></caption><media xlink:href="1745-6215-10-105-S6.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S7"><caption><title>Additional file 7</title><p>MRI DTI.</p></caption><media xlink:href="1745-6215-10-105-S7.DOC" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S8"><caption><title>Additional file 8</title><p>MRI MTLT in AD.</p></caption><media xlink:href="1745-6215-10-105-S8.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S9"><caption><title>Additional file 9</title><p>MRI DTI in AD.</p></caption><media xlink:href="1745-6215-10-105-S9.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S10"><caption><title>Additional file 10</title><p>Paramedic data checklist.</p></caption><media xlink:href="1745-6215-10-105-S10.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S11"><caption><title>Additional file 11</title><p>Pre-hospital CRF-LAND.</p></caption><media xlink:href="1745-6215-10-105-S11.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S12"><caption><title>Additional file 12</title><p>Pre-hospital CRF-AIR.</p></caption><media xlink:href="1745-6215-10-105-S12.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S13"><caption><title>Additional file 13</title><p>In-hospital case report form.</p></caption><media xlink:href="1745-6215-10-105-S13.PDF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>Funding for this study was provided in part from the Defense Research and Development Canada (DRDC). Grant no. w7711-027801/001/TOR (Government of Canada). The investigators would like to acknowledge the assistance of Sandy Malhi, Vincenza Notarangelo, Jennifer Long, Pang Shek (DRDC), Boris Bojilov, Amanda White-McFarlan, Jane Topolovec-Vranic, Jennifer Shield, Josh Sullovoy, Mark Etherington, Dean Popov, Ori Rotstein, Rory O'Neil and Welson Ryan for their contribution to the preparation of this protocol.</p><p><bold><italic>Steering Committee</italic></bold>: Laurie J. Morrison (chair), Sandro B. Rizoli, Andrew J. Baker, Donald T. Stuss, Sandra Black, Shawn G. Rhind, Russell MacDonald, P. Richard Verbeek, Brian Schwartz, Merita Simitciu, Tyrone Perreira, Boris Bojilov, Amanda White-McFarlan, Jane Topolovec-Vranic, Jennifer Shield, Josh Sullovoy, Mark Etherington, Rory O'Neil, Dean Popov, Ori Rotstein.</p><p><bold><italic>Data Management Committee: </italic></bold>Jennifer Long (chair), Anna Trompeo, Marco Katic, Merita Simitciu, Rosa De Angelis, Alex Kiss, Laurie Morrison.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Wade</surname><given-names>CE</given-names></name><name><surname>Grady</surname><given-names>JJ</given-names></name><name><surname>Kramer</surname><given-names>GC</given-names></name><name><surname>Younes</surname><given-names>RN</given-names></name><name><surname>Gehlsen</surname><given-names>K</given-names></name><name><surname>Holcroft</surname><given-names>JW</given-names></name><article-title>Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension</article-title><source>J Trauma</source><year>1997</year><volume>42</volume><issue>5 Suppl</issue><fpage>S61</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1097/00005373-199705001-00011</pub-id><pub-id pub-id-type="pmid">9191698</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Simma</surname><given-names>B</given-names></name><name><surname>Burger</surname><given-names>R</given-names></name><name><surname>Falk</surname><given-names>M</given-names></name><name><surname>Sacher</surname><given-names>P</given-names></name><name><surname>Fanconi</surname><given-names>S</given-names></name><article-title>A prospective, randomized, and controlled study of fluid management in children with severe head injury: lactated Ringer's solution versus hypertonic saline</article-title><source>Crit Care Med</source><year>1998</year><volume>26</volume><issue>7</issue><fpage>1265</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1097/00003246-199807000-00032</pub-id><pub-id pub-id-type="pmid">9671379</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Walker</surname><given-names>PM</given-names></name><name><surname>Romaschin</surname><given-names>AD</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>Piovesan</surname><given-names>J</given-names></name><article-title>Lower limb ischemia: phase 1 results of salvage perfusion</article-title><source>J Surg Res</source><year>1999</year><volume>84</volume><issue>2</issue><fpage>193</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1006/jsre.1999.5641</pub-id><pub-id pub-id-type="pmid">10357919</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Mattox</surname><given-names>KL</given-names></name><name><surname>Maningas</surname><given-names>PA</given-names></name><name><surname>Moore</surname><given-names>EE</given-names></name><name><surname>Mateer</surname><given-names>JR</given-names></name><name><surname>Marx</surname><given-names>JA</given-names></name><name><surname>Aprahamian</surname><given-names>C</given-names></name><name><surname>Burch</surname><given-names>JM</given-names></name><name><surname>Pepe</surname><given-names>PE</given-names></name><article-title>Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The U.S.A. Multicenter Trial</article-title><source>Ann Surg</source><year>1991</year><volume>213</volume><issue>5</issue><fpage>482</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">1708984</pub-id><pub-id pub-id-type="doi">10.1097/00000658-199105000-00014</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Lancaster</surname><given-names>GA</given-names></name><name><surname>Dodd</surname><given-names>S</given-names></name><name><surname>Williamson</surname><given-names>PR</given-names></name><article-title>Design and analysis of pilot studies: recommendations for good practice</article-title><source>J Eval Clin Pract</source><year>2004</year><volume>10</volume><issue>2</issue><fpage>307</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1111/j..2002.384.doc.x</pub-id><pub-id pub-id-type="pmid">15189396</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="other"><article-title>Provincial Advanced Life Support Standards. version 1.1</article-title><year>2000</year><ext-link ext-link-type="uri" xlink:href="http://www.cepcp.ca/main/paramedic/ems/ALS.Pt.%20Care%20Standards.pdf">http://www.cepcp.ca/main/paramedic/ems/ALS.Pt.%20Care%20Standards.pdf</ext-link></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Kovacevic</surname><given-names>N</given-names></name><name><surname>Lobaugh</surname><given-names>NJ</given-names></name><name><surname>Bronskill</surname><given-names>MJ</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Feinstein</surname><given-names>A</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><article-title>A robust method for extraction and automatic segmentation of brain images</article-title><source>Neuroimage</source><year>2002</year><volume>17</volume><issue>3</issue><fpage>1087</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1006/nimg.2002.1221</pub-id><pub-id pub-id-type="pmid">12414252</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>FQ</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>Leibovitch</surname><given-names>FS</given-names></name><name><surname>Callen</surname><given-names>DJ</given-names></name><name><surname>Lobaugh</surname><given-names>NJ</given-names></name><name><surname>Szalai</surname><given-names>JP</given-names></name><article-title>A reliable MR measurement of medial temporal lobe width from the Sunnybrook Dementia Study</article-title><source>Neurobiol Aging</source><year>2003</year><volume>24</volume><issue>1</issue><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(02)00013-1</pub-id><pub-id pub-id-type="pmid">12493550</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Rudkin</surname><given-names>TM</given-names></name><name><surname>Arnold</surname><given-names>DL</given-names></name><article-title>Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders</article-title><source>Arch Neurol</source><year>1999</year><volume>56</volume><issue>8</issue><fpage>919</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1001/archneur.56.8.919</pub-id><pub-id pub-id-type="pmid">10448796</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Basser</surname><given-names>PJ</given-names></name><name><surname>Pierpaoli</surname><given-names>C</given-names></name><article-title>Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI</article-title><source>J Magn Reson B</source><year>1996</year><volume>111</volume><issue>3</issue><fpage>209</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1006/jmrb.1996.0086</pub-id><pub-id pub-id-type="pmid">8661285</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Swartz</surname><given-names>RH</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>St George-Hyslop</surname><given-names>P</given-names></name><article-title>Apolipoprotein E and Alzheimer's disease: a genetic, molecular and neuroimaging review</article-title><source>Canadian Journal of Neurological Sciences</source><year>1999</year><volume>26</volume><issue>2</issue><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">10352866</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Swartz</surname><given-names>RH</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>Feinstein</surname><given-names>A</given-names></name><name><surname>Rockel</surname><given-names>C</given-names></name><name><surname>Sela</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>FQ</given-names></name><name><surname>Caldwell</surname><given-names>CB</given-names></name><name><surname>Bronskill</surname><given-names>MJ</given-names></name><article-title>Utility of simultaneous brain, CSF and hyperintensity quantification in dementia</article-title><source>Psychiatry Research</source><year>2002</year><volume>116</volume><issue>1-2</issue><fpage>83</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/S0925-4927(02)00068-9</pub-id><pub-id pub-id-type="pmid">12426036</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Dade</surname><given-names>LA</given-names></name><name><surname>Gao</surname><given-names>FQ</given-names></name><name><surname>Kovacevic</surname><given-names>N</given-names></name><name><surname>Roy</surname><given-names>P</given-names></name><name><surname>Rockel</surname><given-names>C</given-names></name><name><surname>O'Toole</surname><given-names>CM</given-names></name><name><surname>Lobaugh</surname><given-names>NJ</given-names></name><name><surname>Feinstein</surname><given-names>A</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><article-title>Semiautomatic brain region extraction: a method of parcellating brain regions from structural magnetic resonance images</article-title><source>Neuroimage</source><year>2004</year><volume>22</volume><issue>4</issue><fpage>1492</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2004.03.023</pub-id><pub-id pub-id-type="pmid">15275906</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="book"><name><surname>Safar</surname><given-names>PaB</given-names></name><name><surname>Nicholas</surname><given-names>G</given-names></name><source>Cardiopulmonary cerebral resuscitation: basic and advanced cardiac and trauma life support; an introduction to resuscitation medicine</source><year>1988</year><edition>3</edition><publisher-name>London: W.B. Saunders</publisher-name></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Dodds</surname><given-names>TA</given-names></name><name><surname>Martin</surname><given-names>DP</given-names></name><name><surname>Stolov</surname><given-names>WC</given-names></name><name><surname>Deyo</surname><given-names>RA</given-names></name><article-title>A validation of the functional independence measurement and its performance among rehabilitation inpatients</article-title><source>Arch Phys Med Rehabil</source><year>1993</year><volume>74</volume><issue>5</issue><fpage>531</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/0003-9993(93)90119-U</pub-id><pub-id pub-id-type="pmid">8489365</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="other"><article-title>COMBI: The Center for Outcome Measurement in BrainInjury</article-title><ext-link ext-link-type="uri" xlink:href="http://www.tbims.org/combi">http://www.tbims.org/combi</ext-link><comment>[cited 2005 February 17]</comment></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Rappaport</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>KM</given-names></name><name><surname>Hopkins</surname><given-names>K</given-names></name><name><surname>Belleza</surname><given-names>T</given-names></name><name><surname>Cope</surname><given-names>DN</given-names></name><article-title>Disability rating scale for severe head trauma: coma to community</article-title><source>Arch Phys Med Rehabil</source><year>1982</year><volume>63</volume><issue>3</issue><fpage>118</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">7073452</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Hall</surname><given-names>K</given-names></name><name><surname>Cope</surname><given-names>DN</given-names></name><name><surname>Rappaport</surname><given-names>M</given-names></name><article-title>Glasgow Outcome Scale and Disability Rating Scale: comparative usefulness in following recovery in traumatic head injury</article-title><source>Arch Phys Med Rehabil</source><year>1985</year><volume>66</volume><issue>1</issue><fpage>35</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3966866</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Gouvier</surname><given-names>WD</given-names></name><name><surname>Blanton</surname><given-names>PD</given-names></name><name><surname>LaPorte</surname><given-names>KK</given-names></name><name><surname>Nepomuceno</surname><given-names>C</given-names></name><article-title>Reliability and validity of the Disability Rating Scale and the Levels of Cognitive Functioning Scale in monitoring recovery from severe head injury</article-title><source>Arch Phys Med Rehabil</source><year>1987</year><volume>68</volume><issue>2</issue><fpage>94</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">3813863</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Wilson</surname><given-names>JT</given-names></name><name><surname>Pettigrew</surname><given-names>LE</given-names></name><name><surname>Teasdale</surname><given-names>GM</given-names></name><article-title>Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use</article-title><source>J Neurotrauma</source><year>1998</year><volume>15</volume><issue>8</issue><fpage>573</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1089/neu.1998.15.573</pub-id><pub-id pub-id-type="pmid">9726257</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Jennett</surname><given-names>B</given-names></name><name><surname>Snoek</surname><given-names>J</given-names></name><name><surname>Bond</surname><given-names>MR</given-names></name><name><surname>Brooks</surname><given-names>N</given-names></name><article-title>Disability after severe head injury: observations on the use of the Glasgow Outcome Scale</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1981</year><volume>44</volume><issue>4</issue><fpage>285</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">6453957</pub-id><pub-id pub-id-type="doi">10.1136/jnnp.44.4.285</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="book"><name><surname>Delis</surname><given-names>D</given-names></name><source>California Verbal Learning Test: Adult Version</source><year>1987</year><publisher-name>San Antonio: The Psychological Corporation</publisher-name><pub-id pub-id-type="pmid">3628618</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="book"><name><surname>Wechsler</surname><given-names>D</given-names></name><source>Wechsler Memory Scale - Revised</source><year>1987</year><publisher-name>New York: The Psychological Corporation</publisher-name></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Rey</surname><given-names>A</given-names></name><article-title>L'examen psychologique dans les cas d'encephalopathie traumatique</article-title><source>Archives de Psychologie</source><year>1941</year><volume>28</volume><fpage>286</fpage><lpage>340</lpage></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="book"><name><surname>Lezack</surname><given-names>M</given-names></name><source>Neuropsychological Assessment</source><year>1983</year><publisher-name>New York: Oxford University Press</publisher-name></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="book"><name><surname>Heaton</surname><given-names>R</given-names></name><source>Wisconsin Card Sorting Test Manual</source><year>1981</year><publisher-name>Odessa, Florida: Psychological Assessment Resources</publisher-name></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="book"><name><surname>Kaplan</surname><given-names>E</given-names></name><source>The Boston Naming Test</source><year>1978</year><publisher-name>Boston: Lea and Febiger</publisher-name></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="book"><name><surname>Golden</surname><given-names>C</given-names></name><source>Stroop Colour and word test: A manual for clincial and experimental uses</source><year>1978</year><publisher-name>Wood Dale: Stoelting Co</publisher-name></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Freedman</surname><given-names>M</given-names></name><name><surname>Black</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>P</given-names></name><name><surname>Binns</surname><given-names>M</given-names></name><article-title>Orbitofrontal function, object alternation and perseveration</article-title><source>Cereb Cortex</source><year>1998</year><volume>8</volume><issue>1</issue><fpage>18</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1093/cercor/8.1.18</pub-id><pub-id pub-id-type="pmid">9510382</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="book"><name><surname>Benton</surname><given-names>A</given-names></name><source>Contributions to Neuropsychological Assessment</source><year>1983</year><publisher-name>New York: Oxford University Press</publisher-name></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="book"><name><surname>Wechsler</surname><given-names>D</given-names></name><source>Manual Wechsler Adult Intelligence Scale</source><year>1997</year><publisher-name>San Antonio: TX: The Psychological Corp</publisher-name></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="book"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Steer</surname><given-names>RA</given-names></name><name><surname>Brown</surname><given-names>GK</given-names></name><source>Beck Depression Inventory</source><year>1996</year><edition>Second</edition><publisher-name>Harcourt Assessment: The Psychological Corporation</publisher-name></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Stuss</surname><given-names>DT</given-names></name><name><surname>Stethem</surname><given-names>LL</given-names></name><name><surname>Hugenholtz</surname><given-names>H</given-names></name><name><surname>Picton</surname><given-names>T</given-names></name><name><surname>Pivik</surname><given-names>J</given-names></name><name><surname>Richard</surname><given-names>MT</given-names></name><article-title>Reaction time after head injury: fatigue, divided and focused attention, and consistency of performance</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1989</year><volume>52</volume><issue>6</issue><fpage>742</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">2746267</pub-id><pub-id pub-id-type="doi">10.1136/jnnp.52.6.742</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Stuss</surname><given-names>DT</given-names></name><name><surname>Binns</surname><given-names>MA</given-names></name><name><surname>Murphy</surname><given-names>KJ</given-names></name><name><surname>Alexander</surname><given-names>MP</given-names></name><article-title>Dissociations within the anterior attentional system: effects of task complexity and irrelevant information on reaction time speed and accuracy</article-title><source>Neuropsychology</source><year>2002</year><volume>16</volume><issue>4</issue><fpage>500</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1037/0894-4105.16.4.500</pub-id><pub-id pub-id-type="pmid">12382989</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Pelinka</surname><given-names>LE</given-names></name><name><surname>Toegel</surname><given-names>E</given-names></name><name><surname>Mauritz</surname><given-names>W</given-names></name><name><surname>Redl</surname><given-names>H</given-names></name><article-title>Serum S 100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma</article-title><source>Shock</source><year>2003</year><volume>19</volume><issue>3</issue><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1097/00024382-200303000-00001</pub-id><pub-id pub-id-type="pmid">12630517</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>Morganti-Kossmann</surname><given-names>MC</given-names></name><name><surname>Satgunaseelan</surname><given-names>L</given-names></name><name><surname>Bye</surname><given-names>N</given-names></name><name><surname>Kossmann</surname><given-names>T</given-names></name><article-title>Modulation of immune response by head injury</article-title><source>Injury</source><year>2007</year><volume>38</volume><issue>12</issue><fpage>1392</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2007.10.005</pub-id><pub-id pub-id-type="pmid">18048036</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Kreimeier</surname><given-names>U</given-names></name><name><surname>Messmer</surname><given-names>K</given-names></name><article-title>Small-volume resuscitation: from experimental evidence to clinical routine. Advantages and disadvantages of hypertonic solutions</article-title><source>Acta Anaesthesiol Scand</source><year>2002</year><volume>46</volume><issue>6</issue><fpage>625</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1034/j.1399-6576.2002.460601.x</pub-id><pub-id pub-id-type="pmid">12059884</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Cuschieri</surname><given-names>J</given-names></name><name><surname>Gourlay</surname><given-names>D</given-names></name><name><surname>Garcia</surname><given-names>I</given-names></name><name><surname>Jelacic</surname><given-names>S</given-names></name><name><surname>Maier</surname><given-names>RV</given-names></name><article-title>Hypertonic preconditioning inhibits macrophage responsiveness to endotoxin</article-title><source>J Immunol</source><year>2002</year><volume>168</volume><issue>3</issue><fpage>1389</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11801680</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Rizoli</surname><given-names>SB</given-names></name><name><surname>Kapus</surname><given-names>A</given-names></name><name><surname>Parodo</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Rotstein</surname><given-names>OD</given-names></name><article-title>Hypertonic immunomodulation is reversible and accompanied by changes in CD11b expression</article-title><source>J Surg Res</source><year>1999</year><volume>83</volume><issue>2</issue><fpage>130</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1006/jsre.1999.5581</pub-id><pub-id pub-id-type="pmid">10329106</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Rizoli</surname><given-names>SB</given-names></name><name><surname>Kapus</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Rotstein</surname><given-names>OD</given-names></name><article-title>Immunomodulatory effects of hypertonic resuscitation on the development of lung inflammation following hemorrhagic shock</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><issue>11</issue><fpage>6288</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">9834118</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Rizoli</surname><given-names>SB</given-names></name><name><surname>Rotstein</surname><given-names>OD</given-names></name><name><surname>Parodo</surname><given-names>J</given-names></name><name><surname>Phillips</surname><given-names>MJ</given-names></name><name><surname>Kapus</surname><given-names>A</given-names></name><article-title>Hypertonic inhibition of exocytosis in neutrophils: central role for osmotic actin skeleton remodeling</article-title><source>Am J Physiol Cell Physiol</source><year>2000</year><volume>279</volume><issue>3</issue><fpage>C619</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">10942712</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Thiel</surname><given-names>M</given-names></name><name><surname>Buessecker</surname><given-names>F</given-names></name><name><surname>Eberhardt</surname><given-names>K</given-names></name><name><surname>Chouker</surname><given-names>A</given-names></name><name><surname>Setzer</surname><given-names>F</given-names></name><name><surname>Kreimeier</surname><given-names>U</given-names></name><name><surname>Arfors</surname><given-names>KE</given-names></name><name><surname>Peter</surname><given-names>K</given-names></name><name><surname>Messmer</surname><given-names>K</given-names></name><article-title>Effects of hypertonic saline on expression of human polymorphonuclear leukocyte adhesion molecules</article-title><source>J Leukoc Biol</source><year>2001</year><volume>70</volume><issue>2</issue><fpage>261</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11493618</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Ward</surname><given-names>TH</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Dean</surname><given-names>E</given-names></name><name><surname>Greystoke</surname><given-names>A</given-names></name><name><surname>Hou</surname><given-names>JM</given-names></name><name><surname>Backen</surname><given-names>A</given-names></name><name><surname>Ranson</surname><given-names>M</given-names></name><name><surname>Dive</surname><given-names>C</given-names></name><article-title>Biomarkers of apoptosis</article-title><source>Br J Cancer</source><year>2008</year><volume>99</volume><issue>6</issue><fpage>841</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604519</pub-id><pub-id pub-id-type="pmid">19238626</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Rizoli</surname><given-names>SB</given-names></name><name><surname>Rotstein</surname><given-names>OD</given-names></name><name><surname>Kapus</surname><given-names>A</given-names></name><article-title>Cell volume-dependent regulation of L-selectin shedding in neutrophils. A role for p38 mitogen-activated protein kinase</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><issue>31</issue><fpage>22072</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.31.22072</pub-id><pub-id pub-id-type="pmid">10419535</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Soriano</surname><given-names>SG</given-names></name><name><surname>Piva</surname><given-names>S</given-names></name><article-title>Central nervous system inflammation</article-title><source>Eur J Anaesthesiol Suppl</source><year>2008</year><volume>42</volume><fpage>154</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1017/S0265021507003390</pub-id><pub-id pub-id-type="pmid">18289434</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Togashi</surname><given-names>H</given-names></name><name><surname>Sakisaka</surname><given-names>T</given-names></name><name><surname>Takai</surname><given-names>Y</given-names></name><article-title>Cell adhesion molecules in the central nervous system</article-title><source>Cell Adh Migr</source><year>2009</year><volume>3</volume><issue>1</issue><pub-id pub-id-type="pmid">19372758</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Loomis</surname><given-names>WH</given-names></name><name><surname>Namiki</surname><given-names>S</given-names></name><name><surname>Hoyt</surname><given-names>DB</given-names></name><name><surname>Junger</surname><given-names>WG</given-names></name><article-title>Hypertonicity rescues T cells from suppression by trauma-induced anti-inflammatory mediators</article-title><source>Am J Physiol Cell Physiol</source><year>2001</year><volume>281</volume><issue>3</issue><fpage>C840</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11502561</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Roumen</surname><given-names>RM</given-names></name><name><surname>Hendriks</surname><given-names>T</given-names></name><name><surname>Ven-Jongekrijg</surname><given-names>J van der</given-names></name><name><surname>Nieuwenhuijzen</surname><given-names>GA</given-names></name><name><surname>Sauerwein</surname><given-names>RW</given-names></name><name><surname>Meer</surname><given-names>JW van der</given-names></name><name><surname>Goris</surname><given-names>RJ</given-names></name><article-title>Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure</article-title><source>Ann Surg</source><year>1993</year><volume>218</volume><issue>6</issue><fpage>769</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">8257227</pub-id><pub-id pub-id-type="doi">10.1097/00000658-199312000-00011</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>TS</given-names></name><name><surname>Tan</surname><given-names>KH</given-names></name><name><surname>Ng</surname><given-names>HP</given-names></name><name><surname>Loh</surname><given-names>MW</given-names></name><article-title>The effects of hypertonic saline solution (7.5%) on coagulation and fibrinolysis: an in vitro assessment using thromboelastography</article-title><source>Anaesthesia</source><year>2002</year><volume>57</volume><issue>7</issue><fpage>644</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2044.2002.02603.x</pub-id><pub-id pub-id-type="pmid">12059821</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Lawrence</surname><given-names>M</given-names></name><article-title>A new classification of head injury based on computerized tomography</article-title><source>Journal of Neurosurgery</source><year>1991</year><volume>75</volume><fpage>s14</fpage><lpage>s20</lpage></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><name><surname>Dick</surname><given-names>WF</given-names></name><name><surname>Baskett</surname><given-names>PJ</given-names></name><name><surname>Grande</surname><given-names>C</given-names></name><name><surname>Delooz</surname><given-names>H</given-names></name><name><surname>Kloeck</surname><given-names>W</given-names></name><name><surname>Lackner</surname><given-names>C</given-names></name><name><surname>Lipp</surname><given-names>M</given-names></name><name><surname>Mauritz</surname><given-names>W</given-names></name><name><surname>Nerlich</surname><given-names>M</given-names></name><name><surname>Nicholl</surname><given-names>J</given-names></name><name><surname>Nolan</surname><given-names>J</given-names></name><name><surname>Oakley</surname><given-names>P</given-names></name><name><surname>Parr</surname><given-names>M</given-names></name><name><surname>Seekamp</surname><given-names>A</given-names></name><name><surname>Soreide</surname><given-names>E</given-names></name><name><surname>Steen</surname><given-names>PA</given-names></name><name><surname>van Camp</surname><given-names>L</given-names></name><name><surname>Wolcke</surname><given-names>B</given-names></name><name><surname>Yates</surname><given-names>D</given-names></name><article-title>Recommendations for uniform reporting of data following major trauma--the Utstein style. An International Trauma Anaesthesia and Critical Care Society (ITACCS) initiative</article-title><source>Br J Anaesth</source><year>2000</year><volume>84</volume><issue>6</issue><fpage>818</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10895765</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>DT</given-names></name><name><surname>Knaus</surname><given-names>WA</given-names></name><article-title>Predicting outcome in critical care: the current status of the APACHE prognostic scoring system</article-title><source>Can J Anaesth</source><year>1991</year><volume>38</volume><issue>3</issue><fpage>374</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/BF03007629</pub-id><pub-id pub-id-type="pmid">2036699</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><name><surname>Knaus</surname><given-names>WA</given-names></name><name><surname>Draper</surname><given-names>EA</given-names></name><name><surname>Wagner</surname><given-names>DP</given-names></name><name><surname>Zimmerman</surname><given-names>JE</given-names></name><article-title>APACHE II: a severity of disease classification system</article-title><source>Crit Care Med</source><year>1985</year><volume>13</volume><issue>10</issue><fpage>818</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1097/00003246-198510000-00009</pub-id><pub-id pub-id-type="pmid">3928249</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><name><surname>Ferreira</surname><given-names>FL</given-names></name><name><surname>Bota</surname><given-names>DP</given-names></name><name><surname>Bross</surname><given-names>A</given-names></name><name><surname>M&#x000e9;lot</surname><given-names>C</given-names></name><name><surname>Vincent</surname><given-names>JL</given-names></name><article-title>Serial evaluation of the SOFA score to predict outcome in critically ill patients</article-title><source>Jama</source><year>2001</year><volume>286</volume><issue>14</issue><fpage>1754</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1001/jama.286.14.1754</pub-id><pub-id pub-id-type="pmid">11594901</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><name><surname>Marshall</surname><given-names>JC</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><name><surname>Christou</surname><given-names>NV</given-names></name><name><surname>Bernard</surname><given-names>GR</given-names></name><name><surname>Sprung</surname><given-names>CL</given-names></name><name><surname>Sibbald</surname><given-names>WJ</given-names></name><article-title>Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome</article-title><source>Crit Care Med</source><year>1995</year><volume>23</volume><issue>10</issue><fpage>1638</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1097/00003246-199510000-00007</pub-id><pub-id pub-id-type="pmid">7587228</pub-id></mixed-citation></ref></ref-list></back></article>